CDXS - Codexis, Inc.
| Previous Close | 18.73 |
| Open | 18.77 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 18.61 - 19.00 |
| 52 Week Range | 12.85 - 23.05 |
| Volume | 325,475 |
| Avg. Volume | 361,798 |
| Market Cap | 1.088B |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.30 |
- GlobeNewswire•27 days ago
Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives
Codexis, Inc. (CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. “The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets,” said Codexis President and CEO John Nicols.
- Motley Fool•last month
Is Codexis a Buy?
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
- GlobeNewswire•2 months ago
Codexis to Present at the Jefferies 2019 Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the Jefferies 2019 Global.
- Simply Wall St.•2 months ago
Who Has Been Selling Codexis, Inc. (NASDAQ:CDXS) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- GlobeNewswire•2 months ago
Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader
Codexis, Inc. (CDXS), a leading protein engineering company, announces the signing of a CodeEvolver® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its proprietary CodeEvolver® protein engineering platform technology to Novartis to develop novel performance enzymes for use in manufacturing pharmaceutical products. Upon completion of the technology transfer, the CodeEvolver® protein engineering platform will be located at a Novartis site.
- GlobeNewswire•2 months ago
Codexis to Participate at Three Investment Conferences in May
REDWOOD CITY, Calif., May 14, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in three upcoming.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CDXS earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 Codexis Inc Earnings Call
- Motley Fool•2 months ago
Codexis Bags Novartis as Software Customer, Stays Course in First Quarter
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
- Insider Monkey•2 months ago
Hedge Funds Have Never Been This Bullish On Codexis, Inc. (CDXS)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
Motley Fool•2 months agoCodexis(CDXS) Q1 2019 Earnings Call Transcript
CDXS earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 5.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Codexis: 1Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 9 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The producer of custom ...
- GlobeNewswire•2 months ago
Codexis Reports First Quarter 2019 Financial Results
Total revenues increase 11% to $15.6 million, product revenue up 30% Recent highlights include Third CodeEvolver® Platform Technology Agreement and Multi-Year Enzyme Supply and.
- Motley Fool•3 months ago
3 Stocks That Could Help You Send Your Kids to College
Offset the rising cost of education with these three companies.
- GlobeNewswire•3 months ago
Codexis Signs Multi-Year Enzyme Supply and Licensing Agreement with Tate & Lyle for the Manufacture of TASTEVA® M Stevia Sweetener
REDWOOD CITY, Calif., April 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a multi-year agreement with Tate &.
- GlobeNewswire•3 months ago
Codexis to Hold First Quarter 2019 Conference Call on May 6
REDWOOD CITY, Calif., April 29, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2019 financial results.
- Simply Wall St.•3 months ago
Investors Who Bought Codexis (NASDAQ:CDXS) Shares Five Years Ago Are Now Up 1053%
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Don't believe it? Then look at the Codexis, Inc. (NA...
- GlobeNewswire•3 months ago
Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign
Codexis, Inc. (CDXS), a leading protein engineering company, announces that Jim Lalonde, Ph.D., Senior Vice President of Research and Development, will resign effective May 31, 2019 to pursue other interests. “Jim has played an integral role over many years with the Codexis team refining and applying our CodeEvolver® protein engineering platform. “I am extremely grateful to all of the past and present scientists at Codexis.
- Motley Fool•4 months ago
3 Stocks Poised for Huge Growth Over the Next Decade
Investors with a long-term mind-set can look to these three stocks to inject growth into their portfolio.
- Zacks•4 months ago
Codexis (CDXS) Q4 Earnings Beat Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 400.00% and -3.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.•4 months ago
Codexis, Inc. (NASDAQ:CDXS) Is Expected To Breakeven
Codexis, Inc.'s (NASDAQ:CDXS): Codexis, Inc. discovers, develops, and sells protein catalysts. The US$1.1b market-cap company announced a latest loss of -US$10.9m on 31 December 2018 for its most recent financialRead More...
- GlobeNewswire•4 months ago
Codexis to Participate in Two Investment Conferences in March
REDWOOD CITY, Calif., March 05, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in two upcoming.
- GuruFocus.com•5 months ago
Codexis Inc (CDXS) Files 10-K for the Fiscal Year Ended on December 31, 2018
Codexis Inc (NASDAQ:CDXS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
- GlobeNewswire•5 months ago
Analysis: Positioning to Benefit within Synchrony Financial, KKR & Co., Life Storage, Unum Group, Codexis, and Finisar — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
